Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the Deferred Investment Award Programme.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications rather than financial performance results.
Material Changes
On April 16, 2012, the Administrators of the Deferred Investment Award Programme notified the Company of an increase in notional interests in Ordinary Shares for specific individuals. This increase resulted from the re-investment of the dividend paid to shareholders on April 12, 2012, at a price of 1,407.25 pence per Share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Type: Increase in notional share interests via dividend re-investment.
- Share Price: 1,407.25 pence per Share.
- Dividend Date: April 12, 2012.
- Notification Date: April 16, 2012.
- Participants: Includes Mr E J Gray, Mr S A Hussain, Mr D S Redfern, Ms C Thomas, Dr P J T Vallance, Ms E Walmsley, Mr C Weber, and Mrs V A Whyte.